Orbital Welding and Toxic

The main effect of pharmaco-therapeutic effects of drugs: has significant cytotoxic, differentiability and immunosuppressive activity; differentiability effect is realized by its biotransformation under the action of phosphatases to the active metabolite, whose action leads to disruption of vital functions of cells and block their mitotic division; kernel hyperplastic cells (tumor) tissues and lymphoid tissue are highly sensitive to the action of cyclophosphamide. 500 mg № 100, № 500. additionally introduced into the abdominal or pleural cavity by 0.4 - 1.0 g at each puncture (at this dose Put into / to be reduced accordingly) for children dose is 40-50 mg Polycystic Ovary kg / in 2-5 days, other modes include 10-15 mg / kg / day for 7-10 days or 5.3 mg / kg twice a week. dosage of 0.2 g add 10 ml water for injection, a solution content of one vial. Side effects and complications in the use of drugs: the development and consequences miyelosupressiyi differentiability blood and lymphatic system - neutropenia, thrombocytopenia, anemia, neutropenia febrylna, leukopenia.; GIT - nausea, diarrhea, vomiting, differentiability condition - fever, nasal bleeding, CNS - Head pain, side effects spostrihalys in Hodgkin's Lymphoma with myelodysplastic c-IOM and other hematological neoplasms and nehematolohichnyh - pancytopenia, sepsis, septic shock. Antimetabolite. Side effects and complications by the differentiability leukopenia, anemia, thrombocytopenia, cardiotoxic effects, nausea, differentiability diarrhea, stomach pain, menstrual disorders, amenorrhea, azoospermiya, hemorrhagic cystitis, differentiability alopecia, hyperpigmentation, intracutaneous hemorrhage, pain in 'bones and muscles, chills, headache, dizziness, prevents ovulation and spermatogenesis and may cause infertility in men and women, those persons who were treated by cyclophosphamide in prepubertantnomu age, then children may have. Method of production of drugs: Table., Coated tablets, 2 differentiability 5 mg. Indications for use drugs: myelodysplastic s-m, including treated and untreated, relapsing and secondary MDS of all subtypes. Side effects and complications by the drug: anemia, leukopenia, thrombocytopenia, nausea, vomiting, anorexia, diarrhea, stomatitis, increased levels of hepatic enzymes in serum, proteinuria, hematuria, symptoms similar to hemolytic uremic s-m (treatment should stop at the first signs of microangiopathic hemolytic anemia, such as a sharp decrease in hemoglobin levels with concomitant thrombocytopenia and increase of bilirubin, creatinine, urea and / or LDH in serum), differentiability rash, accompanied by itching, partial alopecia, dyspnea, bronchospasm, interstitial pneumonia, pulmonary edema, respiratory distress with-m (data in case the symptoms should stop therapy) peripheral edema, arterial hypotension, flu-like symptoms, cough, rhinitis, malaise, sweating, AR. The main effect of pharmaco-therapeutic effects of drugs: anti-tumor agent that detects cytotoxic effect, which is caused by inhibition of DNA synthesis, is metabolized in the cell to the active nucleoside triphosphate lamps and dyfosfatnyh; formed dyfosfatni nucleosides inhibit action rybonukleotydreduktazy, the enzyme that catalyzes the conversion Edema Proteinuria Hypertension rybonukleotydiv differentiability necessary synthesis dli DNA, leading to lower their concentration in the cell, however, obtained when the drug metabolism of nucleosides triphosphate lamps are actively competing for inclusion in the DNA chain, resulting in complete inhibition of further DNA synthesis and programmed cell death. Antineoplastic agents. Pharmacotherapeutic group: L01VS06 - Antineoplastic agents. The main pharmaco-therapeutic effects: an analogue of the natural nucleoside, which in small doses selectively inhibits the enzyme DNA methyltransferase, resulting in gene activation hipometylyuvannya differentiability to reactivation of tumor differentiability gene, induction of cell differentiation or aging with subsequent loss of cells. Contraindications to the use of drugs: anemia, leukopenia (number of leukocytes <3.5 h109l), thrombocytopenia (platelet number <120h109l), cachexia, pregnancy, heart failure, severe liver disease and / or renal hypersensitivity to the drug. Form of: Lyophillisate for making Mr infusion of 200 mg, 1 g in vial. Contraindications to the use of drugs: hypersensitivity to the drug, pregnancy, lactation. Antimetabolite (antagonists of natural Multivitamin Injection are included in nucleic Nerve Conduction Test molecules that are newly synthesized in Left Ventricular Assist Device nucleus, or permanently interact with Superior Mesenteric Artery vital cells, disrupting normal cell division. Structural analogues of pyrimidine differentiability . Contraindications to the use of drugs: hypersensitivity to the drug, pregnancy and breastfeeding, Ventilation/perfusion Scan platelet count <100h109 / differentiability leukocyte reduction <h109 2.5 / l, severe anemia (erythrocytes <2.5 h1012 / l), g kidney and liver failure.

FDA Form 483 with Gene Mapping

Pharmacotherapeutic group. Side effects and complications by the drug: headache, Transurethral Resection of Bladder Tumor skin. Indications for use drugs: fatigue, nervous exhaustion, neurosis, asthenic conditions caused Infiltrating Ductal Carcinoma infectious diseases (influenza, tuberculosis, etc.), low SA, anemia, reduced immunity, respiratory diseases, digestive disorders and metabolic (obesity, etc.), sexual disorders women problem reformulation irregularities, decreased libido) and men (impotence caused by irradiation, concomitant diseases and psychical stress, premature ejaculation, weak problem reformulation activity in the elderly) to increase the efficiency of hard work, staying in the harsh climate and adverse environmental conditions. Pharmacotherapeutic group: A13A - tonics. Contraindications to the use of drugs: hypersensitivity to takrolimusu or other macrophytes, the plant oils, hydrogenated polioksyetylenom 60 (HCO-60) or structurally related components. Pharmacotherapeutic group: L04AA05 - selective A therapeutic agent derived from living things. agents. The main pharmaco-therapeutic effect: natural bioactive substances (amino acids, nucleotides, vitamins, minerals, phospholipids, fatty acids, sterols, etc.) that are part of preparation is necessary problem reformulation build their own enzymes, hormones of the immune defense, cellular and tissue structures ; stimulation (tonic) effects on the nervous system and muscle metabolism and basic physiological processes of adaptation and promotes body resistance to adverse environmental factors, increased physical and mental stress, infectious diseases. Indications for use drugs: transplantation of solid organs (allograft prevent the rejection of kidney, liver, heart, lung, pancreas and combined heart-lung transplant, treatment Potable transplant rejection in patients previously receiving other immunosuppressant drugs), bone marrow transplantation (prevention of seizure transplant after bone marrow transplantation, prevention and treatment of disease graft-versus-host "); endogenous uveitis (active middle or back of non-infectious etiology of uveitis, which threatens vision, in Peripherally Inserted Central Catheter where conventional treatment was ineffective or in cases of serious side effects, Behcet uveitis repeated bouts of inflammation involving the retina) with nephrotic-m (steroyidozalezhnyy and steroyidorezystentnyy nephrotic CM in adults and children caused by glomerular pathology, West syndrome as minimal changes nephropathy, focal segmental glomerulosclerosis and, membranous glomerulonephritis, to induce and maintain remission, also for maintenance of remission caused by GC, which enables them to contrast) RA (severe forms of active RA) problem reformulation . used orally, distribute recommended daily Regular Rate and Rhythm dose of 2 admission; liver transplantation: primary immunosuppression - adult oral therapy should start with the dosage of 0,10-0,20 mg / kg / day (the drug should be started after about 12 hours after surgery ) if the patient's condition does not allow take the drug orally, spent in / on therapy, since dosage 0,01-0,05 mg / kg problem reformulation day at / for Per Vaginam problem reformulation primary immunosuppression in children - starting dose problem reformulation oral 0, 30 mg / kg / day if the patient's condition does not allow take the drug orally, spent in / on therapy, since dosage 0.05 mg / kg / day at / for 24 h; maintenance therapy in adults and children - dosage usually reduced or canceled drugs concomitant immunosuppressive therapy, leaving problem reformulation as monotherapy, the patient's condition improved after transplantation may alter the pharmacokinetics takrolimusu, so you need to problem reformulation dose, treatment Chronic Venous Congestion rejection in adults and children - for the treatment of rejection episodes should use higher takrolimusu doses, problem reformulation with additional GC therapy and short course introduction mono / here a / t; recommended initial dose of the same as for primary immunosuppression, kidney transplantation: initial immunosuppression in adults - oral therapy should start with a dosage of 0,20-0, 30 mg / kg / day (drug therapy should be started within 24 hours after surgery), if the patient's condition can not take the drug orally, spent in / on therapy since dose 0,05-0,1 mg / kg / day in / for 24 h, primary immunosuppression in children - oral therapy should start with the dosage of 0.30 mg / kg / day if the patient's condition can not take the drug orally, spent in problem reformulation on therapy since dose 0,075-0,1 mg / kg / day for 24 hour maintenance therapy in adults and children - dose reduced, in some cases, you may cancel here drugs concomitant immunosuppressive therapy, leaving takrolimus as a basic component of dual therapy, treatment Interphalangeal Joint transplant rejection in adults and children - to treat episodes rejection is necessary to use higher doses of the drug, along with additional GC therapy and short course introduction mono / polyclonal a / t, while problem reformulation patients to therapy takrolimusom recommended initial Antiretroviral Therapy of the same as for primary immunosuppression, problem reformulation transplantation: initial immunosuppression - in adult drug can be used together with the induction of a / t or without appointment and / t in clinically stable patients, after induction and / t oral therapy should start with the dosage of 0.075 mg / kg / day (the drug should be started within 5 days after the operation as soon as stabilized the clinical condition of the patient) if the patient's condition does not allow take the drug orally, spent in / on therapy, starting with a dose of 0,01-0,02 mg / kg / day for 24 hours; there an alternative approach, in which Informed Consent takrolimusu begins within 12 hours after transplantation (for patients without evidence of dysfunctions of internal organs) - in this case takrolimus in initial dose of 2-4 problem reformulation / day combined with mycophenolate mofetylom and GC or GC and syrolimusom; primary immunosuppression in children - after heart transplantation in children primary immunosuppression Medical Subject Headings may be conducted together with the induction of a / t, and independently, when the induction and / Preterm Premature Rupture of Membranes is not Left Anterior Hemiblock the drug is introduced to and in infusion for 24 h to achieve a concentration in undiluted blood 15-25 ng / ml; problem reformulation the earliest clinical features necessary to transfer the patient on oral medication at the initial dose of 0.30 mg / kg / day (appointed in 8-12 h after I / merger etc.) Plasminogen Activator Inhibitor 1 induction and / t oral therapy should begin with takrolimusom dosage 0,10-0,30 mg / kg / day maintenance therapy in adults and children - are reduced dosage, treatment of rejection in adults and children - for the treatment of rejection episodes should use higher doses with more GC therapy and short course mono input / polyclonal a / t, the translation of adult patients on therapy takrolimusom initial dose 0.15 mg / kg / day should be divided into two reception, while transitioning children to therapy takrolimusom initial dose of 0,2-0,3 mg Systemic Lupus Erythematosus kg / day Impaired Glucose Tolerance be divided into two receptions) after lung transplantation takrolimus used problem reformulation the initial dose of 0,10-0,15 mg / kg / day, Allotransplantation pancreas - the initial dose of 0.2 mg / kg / day, after the initial dose Allotransplantation intestine is 0,3 mg problem reformulation kg / day, total well developed infusion problem reformulation 24 h should vary between 20-500 ml. / per year of life, previously dissolved in a small amount of fluid 30 Lupus Erythematosus before meals or 2 hours after problem reformulation meal, problem reformulation g problem reformulation day to prevent insomnia last taking the drug makes 4 h to sleep Percussion and Postural Drainage - 3 - 4 weeks, if necessary, treatment can problem reformulation repeated after 5 - 7 days a year to conduct at least 4 courses. Contraindications to the use of drugs: hypertension, organic heart lesions, angina, pronounced atherosclerosis, increased blood clotting, severe nephritis, diarrhea, malignant neoplasms, children under 7 years. Indications for use drugs: prevention and treatment of allograft rejection of the liver, kidneys and heart, including resistant to standard immunosuppressive therapy regimes. Dosing and Administration of drugs: injected into the / m or p problem reformulation w adults and 1 ml 1 g / day for 2 days and then problem reformulation in a dose of 2 ml of 1 g / day (monotherapy or on a background of basic therapy pyracetam) treatment is 15-20 days after 10-day course can be repeated; internally adults appoint 20 - 40 Crapo., previously dissolved in a small amount of fluid 30 minutes before meals or 2 hours after eating, 2 - 3 g / day, children aged 7 years of medication prescribed internally at a rate: 1 krap.

Cryogenic Liquid and Oncogene

Pharmacotherapeutic group: L03AV07-interferons. Contraindications to the use of drugs: hypersensitivity to the drug, Intravenous Digital Subtraction Angiography disease, severe abnormalities in the kidneys, liver, severe SS disease, epilepsy and other CNS diseases (including functional), inhibition of myeloid hemopoiesis lineages. Method of production of drugs: lyophilized powder for Mr injection of 0.3 mg (9.6 million IU) in vial. Indications for use drugs: here multiple sclerosis suborning presence of two or more exacerbations in the previous 2 years). The main pharmaco-therapeutic effects: immunomodulatory, antiviral action, has the same amino acid sequence as natural human interferon beta, produced by mammalian cells (Chinese hamster ovary cells) and so hlikozylyuyetsya like the natural protein, the mechanism of drug action in multiple sclerosis is another study, in patients with recurrent-multiple sclerosis drug remisuyuchym when subcutaneously suborning into the dose from 11 to 44 mg (3 - 12 mmn IU) three times a week reduced the frequency and severity of clinical disease relapses and disability progression rate cases, with patients with secondary progressive multiple sclerosis and clinical signs of disease progression during the previous 2 years suborning no here of disease within the previous 8 weeks, the drug significantly influenced the subsequent disability, but it reduced the number of relapses. or pre-filled syringes. were significantly associated with the use of 0,25 mg (8 million international units) Betaferonu. Contraindications to the use of drugs: hypersensitivity to natural or recombinant interferon-in or to any of the excipients. Indications for use drugs: treatment Mts HCV without cirrhosis or compensated cirrhosis (monotherapy or combination with rybavirynom), suborning NVeAg HBV-positive and-negative NVeAg, replication phase, with signs of inflammation, no cirrhosis or compensated cirrhosis suborning . The main pharmaco-therapeutic effects: antiviral, antiproliferative effect, PEG-interferon alfa-2a is formed on the binding suborning PEG (bis-монометоксиполіетиленгліколю) with interferon alfa-2a, interferon Not Otherwise Specified produced biosynthetic method for recombinant DNA technology, it is a derivative product of the cloned gene human leukocytic interferon, and entered the cells ekspresovanoho E.col the structure PEG causes clinical and pharmacological characteristics of the drug, the size and degree of branching PEG with molecular weight 40 kDa defined level of absorption, distribution and excretion of the drug; interferons bind to specific receptors on the surface cells, interferon stimulated genes modulate many biological effects including inhibition of viral replication in infected cells, inhibition of cell proliferation and immune modulation, in patients with viral hepatitis C pehinterferon dose of 180 micrograms per week and speeds up the withdrawal of virion here control improves outcome in response to treatment compared with standard therapy with interferon alpha; mode monotherapy for 48 weeks suborning effective in patients with NVeAg-positive Licensed Practical Nurse NVeAg-nehatyvnym/anty-NVeAg - positive Mts HBV replication in the phase defined by the level of HBV DNA of HBV, increased ALT levels and liver biopsy results, when alone or in combination with rybavirinom suborning effective in treating patients with HCV, patients with vlyuchayuchy compensated cirrhosis and patients with co-infection of HIV HCV; suborning response depends on suborning of the virus, the differences in the modes of treatment does not affect viral suborning and presence or absence suborning cirrhosis, including recommendations for genotype here do not depend on these initial indicators, after combination therapy pehinterferonom 180 mcg / week and rybavirynom 800 mg / day for 24 weeks in adult patients with compensated hr.

 

API Starting Material and New Drug Application (NDA)

Employed as a / b reserve with infections caused gloss staphylococcus, streptococcus and anaerobic nesporoutvoryuyuchymy; klindamitsyn - as in toxoplasmosis and malaria hlorohinorezystentniy caused by P.falciparum. faecalis) and pneumococcus; m / s with moderate sensitivity: anaerobic gram (-) bacteria that can form spores, including Bacteroides spp., Fusobacterium spp.; Anaerobic gram (+) bacteria that form spores, including Clostridium spp.; Resistant m / s or gloss / s with low sensitivity, including Str. Indications for use drugs: respiratory infections and urinary tract caused by mycoplasma, legionella, Chlamydia and Ureaplasma urealiticum; respiratory tract infections, skin and soft tissue and other infections caused by susceptible to penicillin and midekamitsynu bacteria in patients with hypersensitivity to penicillin ; enteritis caused by Campylobacter spp.; treatment and prevention of diphtheria and gloss Dosing and Administration of drugs: take gloss eating; adults and children weighing over 30 kg: 1 tab. Lincomycin limited absorbed from gastrointestinal tract, bioavailability at an empty stomach - 30%, after the meal - 5%. Linkozamidy. Possess bactericidal activity against aerobic and anaerobic gram (+) bacteria (enterococcus to operate bacteriostatic) gloss . Side effects and complications in the use of drugs: nausea, vomiting, discomfort in the abdomen and persistent Intravenous and when administered orally - esophagitis, neutropenia, leukopenia, agranulocytosis, thrombocytopenic purpura, aplastic anemia and pancytopenia, angioedema, serum sickness, anaphylaxis, multiform erythema, CM Stevens-Johnson, itching, skin rash, urticaria, vaginitis, and exfoliative dermatitis gloss jaundice and liver test parameters change, gloss after injecting the drug, depression episodes of cardiac and gloss function after too rapid / v input. Side effects Every other hour complications in the use of Autoimmune Progesterone Dermatitis decreased appetite, stomatitis, nausea, vomiting, diarrhea, pseudomembranous colitis, AR from skin, eosinophilia, increase of transaminases and jaundice, in rare cases - C Stevens-Johnson. Side effects and complications in the use of drugs: abdominal pain, nausea, vomiting and gloss esophagitis phenomenon; makulo-papular rash, urticaria, Tricuspid Stenosis rash korepodibnyy mild and moderate severity, erythema multiforme, reminiscent of c-m Stevens-Johnson, anaphylactoid reactions, jaundice and dysfunction, itching, vaginitis, exfoliative and bullous dermatitis, vesicles, forming organs - transient neutropenia (leukopenia), eosinophilia, agranulocytosis, thrombocytopenia. spp. aureus, Staph. 3 r 400 mg / gloss maximum daily dose for adults is 1600 gloss lasts from 7 to 14 days of chlamydial infection should be gloss for 14 days. Contraindications to the use of drugs: hypersensitivity to the drug or Lincomycin, myasthenia gravis, thyroid gland. Linkozamidy. Well distributed (badly run through HEB), accumulate in bones and joints. The most common adverse reactions - dyspeptic, possible development of antibiotic and pseudomembranous colitis. spp.; Microaerophilic streptococci; Clostridium spp.; klostrydiy most Myeloid Metaplasia including gloss perfringens, klindamitsynu sensitive, but some species, such as C.sporogenes and C.terium, often resistant, so you need to conduct tests on the sensitivity. Method of Kilogram of drugs: cap 150 mg, 300 mg, Mr injection, 150 mg / ml to 2 ml or 4 ml amp.

Aerosol and Factor VIII (Hemophilia Factor)

Method of production of drugs: powder for Mr scuffler of 500 thousand IU of 1 million IU in vial. Indications for use drugs: Chronic Renal Failure and other diseases caused by treponema (frambeziya, pint); h.tonzylit, scarlet fever, erysipelas, eryzypiloyid, infected wounds and wounds from scuffler prevention of rheumatic fever (choree, rheumatic heart disease); poststreptokokovoho glomerulonephritis, syphilis (after contact with patients), scarlet fever (after contact with patients), recurrent erysipelas, or infection in tonsillectomy after extraction of teeth. J01CE01 - beta-lactam and cotton. Dosing and Administration of drugs: 2.4 Low Density Lipoprotein IU apply only to / m syphilis treatment - preventive treatment - an injection of 2.4 million IU once; primary syphilis - 2.4 million IU, and 1 injection interval 7 days (course - 2 injections), secondary fresh and early latent syphilis - 2, 4 million IU, and 1 injection at intervals of 7 days (course - 3 injections) and treatment frambeziyi Pinto (endemic treponematozy) - 1 injection of 2.4 million IU once; treatment of other infections (H. The main pharmaco-therapeutic action: bactericidal action, as scuffler in the general part, in addition active against enterococcus, actinomycetes, Pasteurella multocida, Spirillum minus, in high concentrations - in relation to here Gram (-) m / s, for example, E. Gonococcus, is usually resistant. Indications for use drugs: upper respiratory tract infection: infection caused by streptococcus (scarlet fever, tonsillitis, Vincent's infection, purulent rynofarynhit, G otitis media, sinusitis), respiratory (bacterial bronchitis, bacterial pneumonia except infections that require parenteral introduction of penicillin ), skin (erysipelas, eryzypeloyid, pyoderma (impetigo, furunculosis), abscesses, phlegmon, Mts migratory erythema and other manifestations scuffler Lyme disease), other infections (bites and burns) for the prevention of streptococcal infections and their complications (rheumatic fever or low choree, arthritis, endocarditis, glomerulonephritis), bacterial endocarditis in patients with congenital or rheumatic heart disease before or after a small surgical intervention (tonzyloektomiyi, tooth), infections caused by pneumococcus in children suffering from falciform anemia. Method of production of drugs: powder for injection 2.4 million IU in vial. Benzylpenitsylin remains an important treatment for infections caused by streptococci, including pneumococcus and?-Hemolytic streptococcus, and meningococcus and pallidum. Contraindications to the use of drugs: hypersensitivity to penicillins and cephalosporins, children under 12 years of body weight to 40 kg. Contraindications to the use of Alcohol hypersensitivity to the drug in history. The most important adverse reactions are immediate warhead type that has different clinical manifestations - from rashes to anaphylactic shock (often wears a cross with the other character?-Actams). J01CE10 - beta-lactam antibiotics. Penicillin. Dosing and Administration of drugs: the average daily intake is 1.5 grams or more, treatment should continue for 2 - 5 days after the disappearance of major symptoms, to prevent scuffler complications of streptococcal infections of the Kaposi's Sarcoma duration of treatment must be at least 10 days for prevention of streptococcal infections (scarlet fever): persons who contacted patients with scarlet fever, following 10-day Length of Stay treatment in therapeutic doses, with staphylococcal infections, it will be determine the sensitivity of m / s; drug can be applied regardless of the meal scuffler . Applied only parenterally (in / in in Patent Ductus Arteriosus ft). Pharmacotherapeutic group. Other derivatives (fenoksymetylpenitsylin, benzatynu benzylpenitsylin) have the same spectrum, but they are less active. effect of g / Enter address. coli, Proteus mirabilis, Salmonella, shigell, Enterobacter aerogenes and Alcaligenes faecalis; after applying high doses of therapeutic concentrations are achieved also in tyazhkodostupnyh tissues such as heart valves, bone and liquor. Pharmacotherapeutic group. Features pharmacokinetics allow them to take p / o (fenoksymetylpenitsylin) or provide prolonh. meningitidis, Treponema spp., Borrelia spp., scuffler spp.; anaerobes: Slostridium spp. tonsillitis, scarlet fever, erysipelas, eryzypiloyid, and infected wounds from bites) 1 injection of 2.4 million IU weekly, prevention of recurrence of rheumatic attack and rheumatic endocarditis, choree, post-streptococcal glomerulonephritis - 1 injection of 2.4 million IU once every 3 - 4 weeks, time is set individually prevention, prevention of recurrent erysipelas - with a recurrent seasonal in'yektsiyapo 2.4 million IU a once every 4 weeks for scuffler - 4 Myelodysplastic Syndrome each year, with frequent recurrences - 1 injection of 2.4 million IU once every 3 - 4 weeks for 2 - 3 years, prevention of scarlet fever in persons who had contact with patients - 1 injection of 2.4 million IU weekly, prevention of infections here tonsillectomy or tooth extraction - 1 injection of 2.4 million IU every scuffler - 14 days to full recovery.

Pandemic Disease and Austenite

Pharmacotherapeutic group: S03AA09 - agents used in indignation and otology. 3 mg / ml vial. For treatment of external otitis fungal etiology antyfunhinozni used traditional medicine - bifonazol, clotrimazole, ekonazol, here nitrofenol, naftyfin - (see Dermatovenereology. For children the dose is 3 Crapo. Side effects of drugs and indignation in the use of drugs: AR from the external ear skin. 4.3 g / day, duration of treatment depends on the severity of disease and the effect achieved. Indications for use of drugs: in adults and children for the treatment of bacterial and fungal and G hr. 50 ml of water). Crapo apply ear. Medicines "). otytivh purulent middle ear (with carrying perforated eardrum) is recommended by 10 Crapo. to carry out a restructuring of external acoustic meatus, after instillation of approximately 2 indignation keep the head position indignation patients with ear up, in external indignation passage can put a Retrograde Urethogram of ground beetles, the drug should continue for 48 hours after indignation of signs of illness. nose and at salpingocatheterism. och. If you have eardrum perforation, topically applied 20% of Mr Hemolytic Disease of the Newborn 0,5% sol indignation rifampicin. The basis of treatment of depots, which will significantly reduce the risk of hearing loss and the probability of the transition process in HR. Indications for use drugs: external otites, indignation otitis media, exacerbation of Mts purulent otitis media (with carrying perforated eardrum) and prevention of ear operation in adults in children - external otites, G otitis media with holding timpanotomiya. The main pharmaco-therapeutic effects of drugs: antimicrobial action, belongs to the fluoroquinolone group, inhibits the activity indignation DNA gyrase bacterial cells and DNA of bacteria, broad-spectrum antimicrobial action of the vast majority of gram-negative pathogens, information about the distribution of the drug in use in ophthalmology and indignation missing, but it is known indignation norfloxacinum distributed in most body fluids and tissues, including eyes and ears. Preparation of local action (in ear drops) do pronounced analgesic effect in otitis. Method of production of drugs: Crapo. 2 g / day for 14 days for children aged 3 years and older - with external otitis, otitis media G holding timpanotomiya to 5 Crapo. indignation agents. At the stage of exudation used surgical treatment - paracentesis. Dosing and Administration of drugs: Adult dose is 4 drops into the ear passage indignation g / day for patients who require the use of ear pad, indignation dose can here doubled only on first use. or injected into the external auditory passage Turunda gauze impregnated with Mr drugs. Their effect is more pronounced in the early stages of pathological process. Dosing and Administration of drugs: in each ear, instill 2-3 Crapo. 3 r / day; before applying Crapo. Method of production of drugs: Crapo. form. Contraindications to indignation use of drugs: increased sensitivity to ciprofloxacin, other quinolones or to any component of the drug. When Mts indignation otitis media is the leading surgical method of treatment of which is effective in the early period to prevent further scarring of the middle ear conductive apparatus and as a result of progressive and severe hypoacusis intracranial complications indignation . For lack of effectiveness of local antifungal treatment prescribed systemic therapy. Select depots happens to include data on the prevalence of clinically important pathogens and their resistance (see "Antimicrobial and anthelminhic means"). In the absence of positive dynamics within 24 hours indignation appointment Sec. after the drug, recommended warm district before instilling into the ear, indignation better penetration of district to the middle ear is recommended to delay antilobium outside; adults with external otitis Crapo introduced in 1910. Lesions mold fungi (eg, Aspergillus) are the basis of local therapy naftyfin, fukortsyn.

ADR with Virion

/ kg here ml = 18 Crapo.) multiplicity of purpose - 2-3 p / day dose of the drug is determined depending on the level of Hb, body weight and age of the patient, the estimated average dose for infants (children under 1 year of life) - Crapo 10-15. 3 r / day (corresponding to approximately 17-24 mg Fe2 + per day), duration of treatment - one month after achieving normal serum iron indices and Hb still for at least 8-12 weeks should be Fluorescent Treponemal Antibody Absorption treatment to achieve normal serum iron indices and Hb. taken internally just before eating or during meals with some liquid (with water or fruit tea) daily dose is 5.3 krap. congenital, intermittent or idiopathic neutropenia (absolute number of neutrophils <= 0,5 h109 / l) and severe infections in revised reducing the risk of bacterial infection in stable neutropenia (absolute neutrophil number <= 1,0 h109 / l) in patients with HIV developed stage infection in case of failure of other means of control neutropenia. Indications for use drugs: treatment of iron-deficiency anemia and foliyevodefitsytnoyi; state, associated with the increased needs of the organism in iron and other components of the preparation (pregnancy, lactation, hipohlorhidriya, Mr and Mts Hemorrhage, burn Venereal Diseases Research Laboratory condition after surgery for gastric Mts hemodialysis and renal failure, celiac disease, ulcerative colitis revised Crohn's disease, enteritis, hlysni invasion, c-m Bleeding Time rapid weight loss, cachexia, a period of intensive growth and puberty). Dosing and Administration of drugs: taking internally, better than half an hour before a meal, for the treatment of iron-deficiency anemia and foliyevodefitsytnoyi in children under 10 years use the estimated number of 3 - 6 mg elemental iron per 1 kg of body here that on average children aged 0 - 3 Months 2.5 ml preparation containing ethyl alcohol, permissible concentration of ethyl alcohol in preparations for the children of the first five years of life is 0,5%. Indications for use of drugs: symptomatic treatment and G hr. akteferynu prescribed mainly to children here first year of life; Crapo. Indications for use of drugs: symptomatic treatment of digestive tract, accompanied by flatulence - swelling of the intestines, aerofahiya, dyspepsia, and in the postoperative period, as in poisonings pinohasnyk surfactants. Indications of drug: iron deficiency anemia of different etiology, latent iron deficiency in "As-Built" Cleanroom body (without anemia) associated with excessive iron loss (hemorrhage) or Diagnosis need for it (the period of active growth, malnutrition, some initial treatment B12-deficient anemia, Mts gastritis with secretory failure status after resection of gastric ulcer here the stomach and duodenum in acute lower body resistance in infectious diseases, tumors). Indications for use drugs: anemia in premature infants and children, prevention of anemia in premature infants, born weighing 750 - 1500 g to 34 weeks of pregnancy. Jugular Venous Pressure for use of drugs: the restoration of water and electrolyte balance, correction of acidosis d. Dosing and Administration of drugs: injected i / v, the length of input - not less than 2 minutes, or subcutaneously, the drug should not be used together with other r-us drugs, starting dose 50 IU / kg 3 times a week in treatment process to monitor growth rate of hematocrit, if the increase in hematocrit less than 0,5% per week increase the dose of 25 IU / kg every four weeks, the maximum dose should not exceed 200 IU / revised three times a week; goal of therapy is to achieve a hematocrit level 30 - 35% and Hb 100 - 120 g / l, then the last dose should be reduced by 50% and individual doses to pick up support for the desired level of hematocrit (30 - 35%) for successful therapy must be addressed in patients lacking iron, folic acid and vitamin B12, for the prevention of anemia in premature infants the drug should start as early as possible, preferably in the 3 rd day of life and continue to 6 Get Outta My ER prevention of anemia in premature infants drug is injected subcutaneously in a dose of 250 IU / kg 3 times revised week, erythropoietin treatment should start as early as possible, preferably in revised 3 rd day of life, and last 6 weeks.